selecting a first-line egfr inhibitor in nsclc
Published 10 years ago • 655 plays • Length 6:46Download video MP4
Download video MP3
Similar videos
-
7:51
nsclc: egfr inhibition and resistance mechanisms
-
2:34
egfr-tkis in first-line egfr metastatic nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
7:31
newer egfr inhibitors in nsclc
-
4:48
third-generation egfr inhibitors in nsclc
-
8:30
third-generation egfr inhibitors in nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
5:47
egfr tkis for upfront treatment of nsclc
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
5:54
frontline alk, egfr inhibition in non-small cell lung cancer
-
1:26
first line treatment of egfr mutation-positive nsclc
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
7:11
the changing landscape of first line treatment for egfr mutation-positive nsclc.
-
6:41
egfr-positive nsclc: treatment at progression
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
4:40
egfr-vegf inhibition for first-line egfr mnsclc treatment